LillyDirect (Zepbound) vs. MEDVi: prices, fine print, and the honest verdict

Tirzepatide pricing

On tirzepatide, MEDVi is the cheaper program at $399 a month all-in versus LillyDirect (Zepbound)'s $449 — a gap of $50 a month, $600 a year, at the 10 mg maintenance basis. LillyDirect (Zepbound): $449 a month all-in at the 10 mg maintenance basis, dose-scaled from a $299 entry, no membership fee. MEDVi: $399 a month all-in at the 10 mg maintenance basis, flat at every dose from 2.5 to 15 mg, no membership fee. Prepaid terms bring the effective rate to $249/mo (12-month plan). Prepaid terms reorder things: MEDVi at $249/mo (12-month plan) — paid up front, with the regulatory-era caveat that locked-in months deserve a read of the refund terms first.

Semaglutide pricing

Only MEDVi publishes a semaglutide price here: Semaglutide runs $299 a month all-in at the standing rate ($179 on intro/plan terms). LillyDirect (Zepbound) doesn't sell compounded semaglutide — its lane is brand fulfillment.

Different products, not just different prices

LillyDirect (Zepbound) fulfills the FDA-approved product — reviewed manufacturing, verified identity and sterility, stable legal status — while MEDVi sells compounded medication: pharmacy-prepared, not FDA-reviewed, and operating under the narrower post-shortage pathways our legal guide tracks. The compounded discount is partly a risk premium; whether it's worth taking depends on the pharmacy behind it and your tolerance for regulatory turbulence.

Transparency

LillyDirect (Zepbound): Source-verified (verified 2026-08-09); names its pharmacy — Eli Lilly direct / retail partners. MEDVi: Source-verified (verified 2026-08-05); dispensing pharmacy not publicly named. In this market, a named pharmacy and a dated, source-verified price are worth real money — they are what let you check the claim instead of trusting it.

Commitment & cancellation

LillyDirect (Zepbound): 45-day refill cadence to keep pricing; no subscription; refill-window rules apply. MEDVi: 12-month plan for the lowest rate; 12-month plan applies to lowest rate.

The gap, compounded over time

A $50/month difference sounds decidable by coin flip until it's annualized: choosing LillyDirect (Zepbound) over MEDVi at the standing rates costs an extra one month, $50; six months, $300; a year, $600; two years of maintenance, $1,200. Only MEDVi publishes a prepaid tier ($249/mo effective), which undercuts even LillyDirect (Zepbound)'s standing $449 by $2,400/year — flexibility versus committed savings, cleanly posed. Every figure is the all-in maintenance basis; the arithmetic reruns from the dataset.

The 24-month ledger

Zoom to the horizon that matters for a chronic-use drug — 24 months — and LillyDirect (Zepbound) bills $10,776 and MEDVi $9,576, a spread of $1,200 for the same molecule at the same 10 mg basis. If prepaid terms held across both years, MEDVi's $249 effective would total $5,976 — $3,600 under even the cheaper standing plan, with the standing caveat that two years of locked funds in this regulatory climate is a real bet, not a rounding choice. Reference rails for the same 24 months: $5,160 at the verified floor, $10,776 on brand Zepbound at maintenance, $8,376 on Wegovy flat.

Two ladders, side by side

The 2.5-to-10 mg climb is the honest stress test: LillyDirect (Zepbound) steps $299 → $399 → $449 and holds $449 from 7.5 mg up (four-month titration: $1,596); MEDVi holds $399 on every rung (four-month titration: exactly $1,596). A flat ladder makes dose decisions purely clinical; a scaled one attaches an invoice to every escalation — including the post-plateau bump from 10 to 12.5 mg that many patients eventually face. Full framework: the titration cost guide.

Three buyers, two invoices

The month-one starter pays $299 at LillyDirect (Zepbound) versus $399 at MEDVi for the 2.5 mg rung — an early edge that reverses once the ladder climbs. The settled 10 mg maintainer — the buyer our basis is built for — pays $4,788/year at MEDVi against $5,388 at the other: $600 of annual daylight for the same molecule and dose. The committed prepayer does best at MEDVi: $249/month effective, $2,988/year, funds up front, refund terms first.

The semaglutide board

Only MEDVi fields a verified semaglutide price here — $299/month all-in (#16 of 19) — while LillyDirect (Zepbound) focuses its published pricing on tirzepatide. For a buyer starting on the cheaper molecule with a likely upgrade later, single-molecule programs mean a future re-shop; dual-molecule ones price the whole arc.

The five normalizations, applied to this pair

1 · All-in, not advertised. LillyDirect (Zepbound)'s ranked figure is $449, with no membership to add; MEDVi's ranked figure is $399, with no membership to add. 2 · Maintenance basis. LillyDirect (Zepbound) scales from $299 to $449, and the 10 mg figure is the one ranked; MEDVi is dose-flat, so its entry and 10 mg figures coincide. 3 · Terms separated. LillyDirect (Zepbound): standing $449, no prepaid tier; MEDVi: standing $399, prepaid $249 effective (12-month plan) — standing rates rank, prepaid effectives are labeled beside them. 4 · Evidence tiered. LillyDirect (Zepbound): source-verified, read 2026-08-09; MEDVi: source-verified, read 2026-08-05. 5 · Pharmacy weighed. LillyDirect (Zepbound) names Eli Lilly direct / retail partners; MEDVi names no pharmacy — in a pharmacy-variance market, disclosure is a scored asset. Run the same five on any roundup you read and most published “cheapest” lists reorder themselves.

Fine print, itemized

LillyDirect (Zepbound): no membership — the medication figure is the billed figure; no subscription; refill-window rules apply; commitment: 45-day refill cadence to keep pricing. MEDVi: no membership — the medication figure is the billed figure; prepaid 12-month plan at $249/mo effective; 12-month plan applies to lowest rate; commitment: 12-month plan for the lowest rate. The pattern to police on both sides is the same: memberships that outlive the medication order, renewal-relative cancellation deadlines, and prepaid terms whose refund language matters more than their discount in a year of live litigation. Cancel in writing; screenshot everything.

Transparency, audited

LillyDirect (Zepbound) carries source-verified pricing (last read 2026-08-09); pharmacy disclosure is its strong suit — Eli Lilly direct / retail partners, manufacturer direct. MEDVi carries source-verified pricing (last read 2026-08-05); its dispensing pharmacy is not publicly named, so the five pharmacy questions (name, 503A/503B status, state licensure, certificate of analysis, formulation) are your pre-purchase homework. Our weighting is unapologetic: in a market of identical molecule names, a dated source-verified price and a named pharmacy are the two claims a buyer can actually check, and they carry 25 of 100 formula points between them — the methodology shows the math, and the pharmacy guide decodes every answer the five questions can return.

Switching between them

Neither program locks the door: a LillyDirect (Zepbound)-to-MEDVi move is a new intake, a new prescription at the new pharmacy, and a written cancellation at the old shop — typically a one-to-two-week overlap if you time the last fill. What does not move with you: prepaid months, membership balances, and any dose paperwork, so re-state your current rung clearly at the new intake.

Refills, shipping, and the week-to-week reality

Past the pricing page, the operational facts are what a subscriber lives with: LillyDirect (Zepbound): shipping included (or same-day retail pickup); consultation bring your own prescription (telehealth partners available); prescription required visit model; a ~45-day refill cadence guards the self-pay tiers (lapse and fills reprice $599–$1,049 until re-enrollment). MEDVi: shipping included; consultation included; async visit model. Cold-chain shipments run 3–7 days across the market; the recurring failure modes are refill-timing gaps and pharmacy backlogs, so whichever program wins here, order refills a week early and confirm the pharmacy’s current turnaround at intake.

Who should pick which

Pick LillyDirect (Zepbound) if a named pharmacy is non-negotiable for you; only the FDA-approved product will do. Pick MEDVi if the $50/month tirzepatide saving is the point; you want a price that survives titration; you'll prepay for the $249 effective rate. Neither answer is universal — which is the argument for choosing from data with dates on it rather than from whichever ad loaded first.

If neither one fits

Two programs never exhaust the market — the nearest substitutes on the verified board are Eden at $408 (dose-scaled, $99 membership included); Remedy Meds at $399 (flat, no membership); Fridays at $359 (flat, no membership) — or skip straight to the rankings page, where every standard “cheapest / best / no-commitment” question is answered in one sourced sentence.

The verdict

On the numbers alone, MEDVi is the cheaper tirzepatide program by $50/mo and it doesn't trade that price for opacity ; LillyDirect (Zepbound)'s case rests on FDA-approved product, better pharmacy disclosure. Both records, with dates and sources, live in the pricing database.